Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Flow Cytometry in Oncology and Immunology Market - A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and Country - Analysis and Forecast, 2022-2032 | ||
By: PR Newswire Association LLC. - 22 Nov 2022 | Back to overview list |
|
NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Global Flow Cytometry in Oncology and Immunology Market to Reach $5,287.4 Million by 2032 Read the full report: https://www.reportlinker.com/p06364002/?utm_source=PRN Global Flow Cytometry in Oncology and Immunology Market Industry Overview The global flow cytometry in oncology and immunology market was valued at $1,653.2 million in 2021 and is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032. The market is driven by factors such as the increasing burden of cancer, expansion of applications in flow cytometry for research activities, innovation in flow cytometry leading to the use of next-generation flow cytometers, and the increasing use of flow cytometry in the identification and diagnosis of immune-deficiency diseases. Market Lifecycle Stage The global flow cytometry in the oncology and immunology market is in the developed phase. The increasing research for flow cytometry for the detection of solid tumors and the leveraging of public-private initiatives to advance R&D in the field of immunology and oncology research are some of the major opportunities in the global flow cytometry in oncology and immunology market. Impact of COVID-19 COVID-19 had a minimal impact on the global flow cytometry in oncology and immunology market.The initial breakout of the pandemic led to an increase in the use of reagents of flow cytometry in research activities and clinical trials. However, the manufacturers witnessed a loss in 2020 due to COVID-19 restrictions and preventive actions such as a reduction in supply chain and sales.Also, there was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for oncology using flow cytometry. Besides these minimal impacts, flow cytometry in oncology and immunology is expected to overcome the impact in the forecast period 2022-2032. Market Segmentation: Segmentation 1: by Offering
The global flow cytometry in oncology and immunology market (by offering) is expected to be dominated by the products segment. Segmentation 2: by Technology
The global flow cytometry in oncology and immunology (by technology) is expected to be dominated by the cell-based flow cytometry segment. Segmentation 3: by Type
The global flow cytometry in oncology and immunology market (by type) is dominated by the oncology segment. Segmentation 4: by Application
The global flow cytometry in oncology and immunology market (by application) is dominated by the translational research segment. Segmentation 5: by End User
The global flow cytometry in oncology and immunology market (by end user) is dominated by the hospitals, diagnostic laboratories, and reference laboratories segment. Segmentation 6: by Region
The global flow cytometry in oncology and immunology market (by region) is dominated by the North America segment. Recent Developments in the Global Flow Cytometry in Oncology and Immunology Market
Demand - Drivers and Limitations Following are the drivers for the global flow cytometry in oncology and immunology market:
The market is expected to face some limitations as well due to the following challenges:
How can this report add value to an organization? Offerings: The offerings segment helps the reader understand the different types of flow cytometry offerings available in the market. Moreover, the study provides the reader with a detailed understanding of products that fall under the two main segments, i.e., products and services. Growth/Marketing Strategy: The global flow cytometry in oncology and immunology market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals.The favored strategy for the companies has been new product offerings to strengthen their position in the market. For instance, in June 2022, Becton, Dickinson and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). Using this technology can help in sorting cells at a very fast speed during flow cytometry. Competitive Strategy: The key players in the global flow cytometry in oncology and immunology market analyzed and profiled in the study involve established and emerging players that offer different products for flow cytometry.Moreover, a detailed competitive benchmarking of the players operating in the global flow cytometry in oncology and immunology market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, mergers, and acquisitions will help the reader understand the untapped revenue pockets in the market. Key Market Players and Competition Synopsis The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some of the players in this market are:
Countries Covered
Read the full report: https://www.reportlinker.com/p06364002/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. Contact Clare: clare@reportlinker.com SOURCE Reportlinker |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |